RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with needs in inflammatory diseases and oncology. Utilizing its proprietary drug discovery and development engine, Co. is developing selective small molecules designed to modulate the immune responses underlying these diseases. Co.'s main inflammation drug candidate, RPT193, and its main oncology drug candidate, FLX475, each target C-C motif chemokine receptor 4, a drug target that potentially has applicability in inflammatory diseases and oncology. The RAPT average annual return since 2019 is shown above.
The Average Annual Return on the RAPT average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether RAPT average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RAPT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|